Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.45 |
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18086455 | 0.92 | BRAF (0.48) | BRAFMAP2K1MRGPRX1HRH1BRD4 | |
| SCHEMBL720442 | 0.90 | MAP2K1 (0.51) | BRAFMAP2K1MAP2K2 | |
| SCHEMBL12656601 | 0.83 | BRAF (0.39) | BRAFMAP2K1MRGPRX1HRH1MAP2K2 | |
| SCHEMBL1516484 | 0.80 | MAP2K1 (0.58) | BRAFMAP2K1MAP2K2 | |
| SCHEMBL1516527 | 0.80 | MAP2K1 (0.45) | BRAFMAP2K1MAP2K2 | |
| SCHEMBL12407095 | 0.79 | MRGPRX1 (0.51) | BRAFMRGPRX1HRH1 | |
| SCHEMBL391647 | 0.78 | MRGPRX1 (0.44) | BRAFMAP2K1MRGPRX1HRH1MAP2K2 | |
| SCHEMBL1516487 | 0.78 | MAP2K1 (0.55) | BRAFMAP2K1MAP2K2 | |
| SCHEMBL1516512 | 0.78 | BRAF (0.48) | BRAFMAP2K1MAP2K2 | |
| SCHEMBL12836734 | 0.78 | BRAF (0.48) | BRAFMAP2K1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-9095581-B2 | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120136030-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2007121481-A2 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136030-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | BRAF 1/4885MAP2K1 71/4885MRGPRX1 2335/4885 |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | BRAF 1/4885MAP2K1 71/4885MRGPRX1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.